The poster will include clinical data as of an April 4, 2025 data cutoff from the Company's ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in ...

Verastem (VSTM) announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application of ...

Lipella Pharmaceuticals (LIPO) announced that its abstract on LP-10 for the treatment of Oral Lichen Planus, OLP, has been accepted for podium ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical ...